摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

哌嗪-1-甲脒 | 45695-84-9

中文名称
哌嗪-1-甲脒
中文别名
1-哌嗪羧胺
英文名称
piperazine-1-carboxamidine
英文别名
piperazine-1-carboximidic acid amide;Piperazine-1-carboximidamide
哌嗪-1-甲脒化学式
CAS
45695-84-9
化学式
C5H12N4
mdl
MFCD04116543
分子量
128.177
InChiKey
ZTWBXCGKRKUYSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    225.9±50.0 °C(Predicted)
  • 密度:
    1.37±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    65.1
  • 氢给体数:
    3
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933599090

SDS

SDS:71842bc66b4ca396ddb606b07765bc45
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-BOC-5-氧代氮杂环庚烷-甲酸乙酯哌嗪-1-甲脒sodium ethanolate 作用下, 以 乙醇 为溶剂, 反应 24.0h, 生成 tert-butyl 4-hydroxy-2-(piperazin-1-yl)-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepine-7-carboxylate
    参考文献:
    名称:
    发现和合成6,7,8,9-四氢-5 H-嘧啶-[4,5- d ]氮杂唑作为新型TRPV1拮抗剂
    摘要:
    利用四氢嘧啶并氮杂卓核作为哌嗪-尿素的生物等效替代物,导致发现了一系列新的TRPV1强效拮抗剂。已经确定四氢嘧啶并氮杂卓具有良好的体外和体内效力以及可接受的物理性质。
    DOI:
    10.1016/j.bmcl.2010.09.023
  • 作为产物:
    描述:
    三乙胺 、 、 哌嗪四氢呋喃N,N-二甲基甲酰胺碳酸氢钠乙酸乙酯magnesium sulfate 作用下, 以 乙腈乙醚1,4-二氧六环 为溶剂, 反应 17.0h, 生成 哌嗪-1-甲脒
    参考文献:
    名称:
    Piperazine amidines as antiviral agents
    摘要:
    本公开提供了式I所描述的化合物,具有药物和生物影响特性,以及它们的制药组合物和使用方法。特别是,本公开涉及具有独特的抗病毒活性的吲哚和氮杂吲哚哌嗪二酰胺衍生物。更具体地,本公开涉及用于治疗HIV和艾滋病的化合物。
    公开号:
    US07396830B2
点击查看最新优质反应信息

文献信息

  • Oxazolone derivatives and uses thereof
    申请人:Syntex (U.S.A.) LLC
    公开号:US06355641B1
    公开(公告)日:2002-03-12
    This invention relates to compounds which are generally alpha1B-receptor antagonists, and which are represented by Formula (I): wherein X, Y, and R1 are as defined in the specification, or individual isomers or racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, and methods for their use as therapeutic agents.
    这项发明涉及一般为α1B-受体拮抗剂的化合物,其由式(I)所代表: 其中X、Y和R1如规范中所定义,或者是各个异构体或消旋或非消旋异构体的混合物,或其药学上可接受的盐或溶剂。该发明还涉及含有这种化合物的药物组合物,以及它们作为治疗剂的使用方法。
  • 1,5-Benzoxathiepin derivatives. I. Synthesis and reaction of 1,5-benzoxathiepin derivatives.
    作者:HIROSADA SUGIHARA、HIROSHI MABUCHI、YUTAKA KAWAMATSU
    DOI:10.1248/cpb.35.1919
    日期:——
    Methyl 3-oxo-3, 4-dihydro-2H-1, 5-benzoxathiepin-4-carboxylates (3a-f) were synthesized by regioselective Dieckmann reaction of methyl 2-methoxycarbonylmethylthiophenoxyacetates (2a-f) [readily prepared from 2-mercaptophenols (la-f)] in fairly good yields. Alkylation of thc ketoester (3b) with alkyl halides gave 4-alkylated derivatives (7 and 8). A substituent at the 2-position on the 1, 5-benzoxathiepin ring was introduced by Dieckmann reaction of methyl ssubstituted 2-methoxycarbonylmethylthiophenoxyacetates (11, 12b and 12f). Thorpe-Ziegler reaction of 2-cyanomethylthiophenoxyacetonitriles (18a-d) gave 3-amino-2H-1, 5-benzoxathiepin-4-carbonitriles (19a-d). Novel heterocycles, 4-amino-11H-pyrimido [4, 5-c] [1, 5] benzoxathiepin derivatives (24-32), were synthesized by the reaction of enaminonitriles (3a and 3b) with amidines or guanidines.
    甲基3-氧基-3, 4-二氢-2H-1, 5-苯并噻噁烯-4-羧酸酯(3a-f)通过区域选择性的Dieckmann反应合成,起始物为甲基2-甲氧基羧基甲基噻吩氧乙酸酯(2a-f,易于由2-巯基苯酚(1a-f)制备而成),产率相当不错。对酮酸酯(3b)进行烷基化反应,使用烷基卤化物得到了4-烷基化衍生物(7和8)。通过对甲基取代的2-甲氧基羧基甲基噻吩氧乙酸酯(11, 12b和12f)进行Dieckmann反应,实现了在1, 5-苯并噻噁烯环的2位引入取代基。对2-氰甲基噻吩氧乙腈(18a-d)进行Thorpe-Ziegler反应,得到3-胺基-2H-1, 5-苯并噻噁烯-4-氰基(19a-d)。通过酰胺腈(3a和3b)与酰胺或胍反应,合成了新型杂环化合物4-氨基-11H-吡咯并[4, 5-c][1, 5]苯并噻噁烯衍生物(24-32)。
  • Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 2. Probing the Indeno Ring Substituent Pattern
    作者:David A. Nugiel、Anup Vidwans、Anna-Marie Etzkorn、Karen A. Rossi、Pamela A. Benfield、Catherine R. Burton、Sarah Cox、Deborah Doleniak、Steven P. Seitz
    DOI:10.1021/jm020171+
    日期:2002.11.1
    We disclose a novel series of indenopyrazole-based cyclin-dependent kinase (CDK) inhibitors. Kinetic experiments confirmed our initial molecular modeling studies that the compounds are competitive with respect to adenosine 5'-triphosphate (ATP) and bind in the kinase ATP pocket. A unique combination of active pharmacophores led us to a series of semicarbazide-based. inhibitors that are highly potent against CDK2 and CDK4 while maintaining selectivity against other relevant serine/threonine kinases. These compounds were active against a transformed human colon cancer cell line (HCT116) while maintaining an acceptable margin of activity against a normal fibroblast cell line. The compounds were found to be highly protein bound in our cell-based assay with the exception of 11k, which maintained a reasonable level of activity in the presence of human plasma proteins.
  • SUGIHARA HIROSADA; MABUCHI HIROSHI; KAWAMATSU YUTAKA, CHEM. AND PHARM. BULL., 35,(1987) N 5, 1919-1929
    作者:SUGIHARA HIROSADA、 MABUCHI HIROSHI、 KAWAMATSU YUTAKA
    DOI:——
    日期:——
  • ——
    作者:YAMADZI MITSUXARU
    DOI:——
    日期:——
查看更多